Novel Gold nanocarriers conjugates for microRNA delivery in ovarian cancer

项目摘要 基于微RNA（miRNA）的治疗剂的体内递送是微RNA治疗的重要但目前具有挑战性的方面。 用于多种疾病的药物开发过程，包括癌症、病毒感染和自身免疫性疾病， 神经退行性疾病我们的长期目标是开发基于证据的临床有用的输送系统 用于改善人类疾病，特别是癌症的治疗。此SC 3的目标 本申请的目的是合成和测试纳米载体试剂以递送以下的寡核苷酸miRNA模拟物（OMM）： miR-18 a（miR-18 a-OMM），在小鼠卵巢癌移植瘤中。实验表明，miR-18 a-OMM 降低卵巢癌细胞的增殖，这种作用部分是由于c-MYC的减少。 表达（c-MYC是卵巢癌细胞中高度丰富的癌基因）。我们的中心假设是， 主客体模型，由主体分子与固体金纳米颗粒（AuNP）共价结合组成 和连接到货物分子（OMM和/或肿瘤细胞靶向配体）的客体分子，将形成一个 用于有效递送miR-18 a-OMM的强的主体-客体纳米载体复合物。了该假设 根据现有文献以及PI和合作者的初步数据制定 laboratories.该项目的理由是，成功完成这些研究可能会产生一个新的 用于在体内递送和检测特异性miRNA的纳米颗粒试剂。根据初步数据， 假设将测试追求两个具体目标：1）合成和表征新的多功能 用于递送miR-18 a OMM的金纳米载体;和2）确定miR-18 a OMM的治疗功效 体内18 α-OMM-金纳米载体。对于第一个目标，该方法涉及修饰Au的表面 具有客体分子的纳米颗粒，以及miRNA和其他配体（需要用于改善稳定性和 复合物的递送效率）与分子（“客体”）形成强包合复合物， Au表面上的宿主分子。为了支持概念验证，在第二个目标下，我们将瞄准mir-18 a 卵巢癌小鼠模型中的OMMin。这一贡献将是巨大的，因为预计 构成了一个重要的一步，在一个连续的研究，最终将导致发展的临床 可用于治疗卵巢癌的纳米颗粒系统。这项研究具有潜在的创新性，因为 通过引入一种新型的纳米颗粒试剂， 专门设计用于在体内递送寡核苷酸模拟物，以沉默卵巢癌内部的特定靶点 活动物的细胞。反过来，这应该转化为对人类更好的治疗。

PROJECT SUMMARY In vivo delivery of MicroRNAs (miRNA)-based therapeutics is an important, but currently challenging aspect of the drug development process for a variety of diseases, including cancer, viral infections, and autoimmune and neurodegenerative disorders. Our long-term goal is to develop evidence-based clinically-useful delivery systems for miRNAs to improve therapies for human disease, in particular for cancer. The objective for this SC3 application is to synthetize and test a nanocarrier reagent to deliver an oligonucleotide miRNA mimic (OMM) of miR-18a (miR-18a-OMM), in ovarian cancer tumors implanted in mice. Experiments showed that miR-18a-OMM reduced the proliferation of ovarian cancer cells, an effect that was in part due to the reduction of c-MYC expression (c-MYC is an oncogene highly abundant in ovarian cancer cells). Our central hypothesis is that a host - and – guest model, consisting of a host molecule covalently bound to a solid gold nanoparticle (AuNP) and a guest molecule attached to the cargo molecule (OMM and/or a tumor-cell-targeting ligand), will form a strong host-guest nanocarrier complex for the efficient delivery of miR-18a-OMM. This hypothesis was formulated based on the existing literature and on preliminary data produced in the PI’s and the collaborator’s laboratories. The rationale for this project is that successful completion of these studies is likely to yield a new nanoparticle reagent for delivering and transfecting specific miRNAs in vivo. Guided by preliminary data, this hypothesis will be tested pursuing two specific aims: 1) To synthetize and characterize new multifunctional gold nanocarriers for delivering of miR-18a OMMs; and 2) To determine the therapeutic efficacy of miR- 18a-OMM-gold nanocarriers in vivo. For the first aim, the approach involves modifying the surface of Au nanoparticles with a guest molecule, and the miRNA and other ligands (needed for improving the stability and delivery efficiency of the complex) with a molecule (a “guest”) that forms strong inclusion complexes with the host molecule on the Au surface. To support proof of concept, under the second aim, we will target mir-18a with an OMMin in ovarian cancer mouse model. This contribution will be significant because it is expected to constitute an important step in a continuum of research that will ultimately lead to the development of a clinically useful nanoparticle system to treat ovarian cancer. The proposed research is potentially innovative because it represents a substantial departure from the status quo by introducing a new type of nanoparticle reagent specifically designed to deliver oligonucleotide mimic in vivo, to silence a specific target inside the ovarian cancer cells in live animals. This, in turn, should translate to better therapy for humans.